- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01252056
A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy
May 7, 2013 updated by: Otsuka Beijing Research Institute
A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy
The efficacy and safety of Cilostazol and Probucol in combination on patients with diabetic nephropathy is better than the single use.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objectives of this study is:
- To evaluate the efficacy of Probucol on deferring nephropathy development of the patients with diabetic nephropathy (including: the change value of urine albumin from the baseline, the rate of the patients with serum creatinine reaching a doubling of the base-line serum creatinine, the rate of the hemodialysis-free survival).
- To evaluate the efficacy of Cliostazol and Probucol in combination on deferring nephropathy development of the patients with diabetic nephropathy
- To evaluate the efficacy of Cilostazol and Probucol in combination on atherosclerosis related biomarkers change. Atherosclerosis related biomarkers include:(a)Endothelium parameter: ICAM-1, vWF, VCAM-1,and McP-1. (b)Finolysis parameter: TM. (c)Inflammation parameter: Hs-CRP; IL-6. (d)Oxidation parameter: Ox-LDL, 8-OHdG. (e)Lipid parameter: TC, LDL-C, HDL-C, TG.
- To evaluate the efficacy of Cilostazol and Probucol in combination on the progress of carotid intima-media thickness (IMT) on patients with diabetic nephropathy.
- To evaluate the safety of Cilostazol and Probucol in combination on the patients with diabetic nephropathy.
Study Type
Interventional
Enrollment (Actual)
353
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijng, Beijing, China
- Beijing Universuty First Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female age 40~75 years old
- Type 2 diabetes mellitus above 6 months
- HbA1c ≤8%
- Twice (above 2-week interval) confirmed urinary albumin at 30-3000µg/mg.cre
- Receive routine dosage ACEI or ARB treatment above 2 months, and the dosage has been fixed for at least 1 month
- LDL-C>100 mg/dL (2.60 mmol/L) and/ or hyperlipidemia patients with Statins treatment
- Free will to sign the informed consent form
Exclusion Criteria:
- Has an allergic history to investigational drugs
- Receive antilipemic agents (except Statins) within the latest 2 months, including Probucol
- Receive antiplatelet or anticoagulation agents (except Aspirin) within the latest 2 months, including Cilostazol
- Rapid progression of nephropathy within the latest 3 months
- Kidney disease caused by other reasons according to medical history
- Serum potassium level less than 3.5 mEq/L or more than 5.5 mEq/L
- Hemorrhagic tendency or hemorrhagic disease (such as alimentary tract hemorrhage, active fundus hemorrhage, etc.)
- Has a myocardial infarction, angina pectoris, or cerebral infarction within the latest 3 months
- Congestive heart failure
- Pregnant, potentially pregnant, or lactating woman
- Severe hepatic inadequacy (AST or ALT is 2.5 times higher than the upper limit of the normal value range)
- Serum creatinine level is 1.5 times higher than the upper limit of the normal value range
- Persistent or hardly controlled hypertension (such as malignant hypertension, SBP≥170 mmHg and/ or DBP≥100 mmHg)
- Severe ventricular arrhythmia (such as multiple and multifocal premature ventricular contractions)
- Has a medical history of cardiac syncope or primary syncope
- Has condition that may prolong QT interval (such as congenital long QT syndrome, taking drugs which prolong QT interval, hypokalemia or hypomagnesemia, etc.), or for man QT interval>450msec, for woman QT interval>470msec
- Has severe complication (such as diabetes mellitus ketoacidosis, nonketotic hyperosmolar diabetic coma, malignant tumor, severe anaemia, severe hematologic diseases, etc.)
- Register other clinical trials within the latest 3 months
- Other conditions that would be excluded from this study according to doctors'judgment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
|
|
Active Comparator: Probucol
Probucol treatment
|
250mg,Bid
|
Active Comparator: Combination
Probucol and Cilostazol
|
50-100mg,Bid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
nephropathy development
Time Frame: 96W
|
After 96-week treatment, compare the efficacy between Probucol group and group control group on deferring nephropathy development of the patients with diabetic nephropathy (including: the change value of urine albumin from the baseline, the rate of the patients with serum creatinine reaching a doubling of the base-line serum creatinine, the rate of the hemodialysis-free survival)
|
96W
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IMT
Time Frame: 48 and 96W
|
After 48-week and 96-week treatment, compare the change value of IMT from the baseline among 3 modality groups.
|
48 and 96W
|
Atherosclerosis related biomarkers
Time Frame: 48 and 96W
|
After 12-week, 48-week and 96-week treatment, compare the change value of atherosclerosis related biomarkers from the baseline among 3 modality groups
|
48 and 96W
|
Nephropathy development
Time Frame: 48 and 96W
|
1.
After 48-week and 96-week treatment, compare the efficacy among 3 modality groups on deferring nephropathy development of the patients with diabetic nephropathy (including: the change value of urine albumin from the baseline, the rate of the patients with serum creatinine reaching a doubling of the base-line serum creatinine, the rate of the hemodialysis-free survival)
|
48 and 96W
|
Adverse events
Time Frame: 96W
|
Incidence of adverse events, clinically relevant abnormal laboratory results before and after treatment (including hemotology, biochemistry, routine urine analysis and glycosylated hemoglobin), abnormal findings of vital sign, physical examination, and 12-lead ECG results
|
96W
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiaohui Guo, Beijing University First Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
April 21, 2010
First Submitted That Met QC Criteria
December 1, 2010
First Posted (Estimate)
December 2, 2010
Study Record Updates
Last Update Posted (Estimate)
May 8, 2013
Last Update Submitted That Met QC Criteria
May 7, 2013
Last Verified
May 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Diseases
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Kidney Diseases
- Diabetic Nephropathies
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Antimetabolites
- Neuroprotective Agents
- Protective Agents
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Antioxidants
- Phosphodiesterase Inhibitors
- Phosphodiesterase 3 Inhibitors
- Cilostazol
- Probucol
Other Study ID Numbers
- 260-09-805-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Nephropathy
-
Assiut UniversityUnknownDiabetic Nephropathy Type 2
-
Zheng GuoNot yet recruitingDiabetic Nephropathy Type 2
-
The Third Xiangya Hospital of Central South UniversityCompletedType 2 Diabetic NephropathyChina
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownDiabetic Nephropathy Type 2Mexico
-
Second Affiliated Hospital, School of Medicine,...Second Affiliated Hospital of Wenzhou Medical University; Lishui Country People...RecruitingDiabetic Nephropathy Type 2 | BiomarkerChina
-
University of Sao Paulo General HospitalCompleted
-
Chinese PLA General HospitalCompletedInsulin Pump Therapy in Treating Diabetic Nephropathy
-
Assiut UniversityNot yet recruitingType 2 DM é Diabetic Nephropathy
-
PfizerTerminatedType 2 Diabetic NephropathyUnited States
-
Chang Gung Memorial HospitalUnknown
Clinical Trials on Probucol
-
Korea Otsuka Pharmaceutical Co., Ltd.CompletedDiabetic NephropathyKorea, Republic of
-
Otsuka Beijing Research InstituteCompleted
-
First Affiliated Hospital of Wannan Medical CollegeBeijing Tiantan HospitalNot yet recruiting
-
Korea Otsuka Pharmaceutical Co., Ltd.Completed
-
Yonsei UniversityKorea Otsuka Pharmaceutical Co., Ltd.Completed
-
Yokohama City University Medical CenterCompleted
-
Otsuka Beijing Research InstituteCompletedAtherosclerosis Cerebral InfarctionChina
-
Korea Otsuka Pharmaceutical Co., Ltd.CompletedPeripheral Artery DiseaseKorea, Republic of
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
Otsuka Beijing Research InstituteCompleted